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Summary
Background The burden of non-alcoholic fatty liver disease (NAFLD) is increasing globally, and a major priority is to 
identify patients with non-alcoholic steatohepatitis (NASH) who are at greater risk of progression to cirrhosis, and who 
will be candidates for clinical trials and emerging new pharmacotherapies. We aimed to develop a score to identify 
patients with NASH, elevated NAFLD activity score (NAS≥4), and advanced fibrosis (stage 2 or higher [F≥2]).
Methods This prospective study included a derivation cohort before validation in multiple international cohorts. The 
derivation cohort was a cross-sectional, multicentre study of patients aged 18 years or older, scheduled to have a liver 
biopsy for suspicion of NAFLD at seven tertiary care liver centres in England. This was a prespecified secondary 
outcome of a study for which the primary endpoints have already been reported. Liver stiffness measurement (LSM) 
by vibration-controlled transient elastography and controlled attenuation parameter (CAP) measured by FibroScan 
device were combined with aspartate aminotransferase (AST), alanine aminotransferase (ALT), or AST:ALT ratio. To 
identify those patients with NASH, an elevated NAS, and significant fibrosis, the best fitting multivariable logistic 
regression model was identified and internally validated using boot-strapping. Score calibration and discrimination 
performance were determined in both the derivation dataset in England, and seven independent international 
(France, USA, China, Malaysia, Turkey) histologically confirmed cohorts of patients with NAFLD (external validation 
cohorts). This study is registered with ClinicalTrials.gov, number NCT01985009.
Findings Between March 20, 2014, and Jan 17, 2017, 350 patients with suspected NAFLD attending liver clinics in England 
were prospectively enrolled in the derivation cohort. The most predictive model combined LSM, CAP, and AST, and was 
designated FAST (FibroScan-AST). Performance was satisfactory in the derivation dataset (C-statistic 0·80, 95% CI 
0·76–0·85) and was well calibrated. In external validation cohorts, calibration of the score was satisfactory and 
discrimination was good across the full range of validation cohorts (C-statistic range 0·74–0·95, 0·85; 95% CI 0·83–0·87 
in the pooled external validation patients’ cohort; n=1026). Cutoff was 0·35 for sensitivity of 0·90 or greater and 0·67 for 
specificity of 0·90 or greater in the derivation cohort, leading to a positive predictive value (PPV) of 0·83 (84/101) and a 
negative predictive value (NPV) of 0·85 (93/110). In the external validation cohorts, PPV ranged from 0·33 to 0·81 and 
NPV from 0·73 to 1·0.
Interpretation The FAST score provides an efficient way to non-invasively identify patients at risk of progressive 
NASH for clinical trials or treatments when they become available, and thereby reduce unnecessary liver biopsy in 
patients unlikely to have significant disease.
Funding Echosens and UK National Institute for Health Research.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license. 
Introduction
Non-alcoholic fatty liver disease (NAFLD) is rising in 
prevalence along with levels of obesity and type 2 diabetes, 
such that it is now the most common cause of chronic 
liver disease worldwide.1 Prevalence in the general 
population is 25–35%, but this rises to 70% in patients 
with obesity and type 2 diabetes.1 Although most patients 
with NAFLD do not progress to advanced fibrosis or 
cirrhosis, the high prevalence of NAFLD means that 
many patients do develop chronic liver disease, and that 
NAFLD is now one of main indications for liver 
transplantation in Europe2 and the USA.3 A key challenge 
is the identification of patients who are at greatest risk of 
clinical progression by way of worsening liver fibrosis, 
and who might benefit from treatment with new 
pharmacotherapies.4,5
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Currently, identification of patients with active NASH 
and significant fibrosis can be done using non-invasive 
markers that risk-stratify liver fibrosis6 or require 
percutaneous liver biopsy. The use of non-invasive markers 
includes algorithms,7 serum bio markers,8 and imaging 
modalities,9 but makes no determination of the presence 
or degree of inflammatory liver injury. The presence of 
non-alcoholic steatohepatitis (NASH) and more profound 
liver cell injury, as determined by measures of steatosis 
(lobular inflammation and ballooning),10 are crucial drivers 
of the development of liver fibrosis in patients with NAFLD 
and will be important in risk stratification.
We present a prespecified secondary analysis of a 
previously published study,11 with the aim of developing 
an algorithm to diagnose, among people with suspected 
NAFLD, those with NASH, significant liver fibrosis (≥F2), 
and elevated NAFLD activity score (NAS≥4). This 
combination of criteria is important, as the presence of 
fibrosis alone is insufficient for recruitment to clinical 
trials. Moreover, the presence of inflammation defined by 
NASH and elevated NAS will be important in identifying 
patients who could benefit from anti-inflammatory 
therapies, as these interventions might not be as relevant 
for patients with fibrosis but no or minimal inflammatory 
injury. Studies have shown that histological responses to 
trial medications are more common in patients with 
elevated NAS.12 We aimed to develop an algorithm to 
identify this subgroup of patients for clinical trial 
eligibility and for optimal prescription of therapies. 
Methods
Study design
This prospective study was done as a derivation cohort 
before validation in multiple global cohorts (named 
external validation cohorts hereafter). The transparent 
reporting of a multivariable prediction model for 
individual prognosis or diagnosis (TRIPOD) guidelines13 
were followed to report the development and internal 
and external validation of the prediction model for 
diagnosis of NASH + NAS ≥ 4 + F ≥ 2 (appendix p 3).14
The derivation cohort was a cross-sectional, prospective, 
multicentre study. Consecutive patients were recruited 
from seven tertiary care liver centres across England 
(University Hospitals Birmingham NHS Foundation 
Trust, Birmingham; Addenbrooke’s Hospital, Cambridge; 
Royal Free Hospital, London; Freeman Hospital, Newcastle 
upon Tyne; University Hospitals Plymouth NHS Trust, 
Plymouth; Queen’s Medical Centre, Nottingham; and John 
Radcliffe Hospital, Oxford). The study was approved by the 
North Wales Research Ethics Committee (13/WA/0385) 
and by the local research ethics committee at each centre. 
The study was done in accordance with the Declaration of 
Helsinki and in agreement with the Inter national 
Conference on Harmonisation guidelines on Good 
Clinical Practice. The primary objective of this study was to 
assess the diagnostic accuracy of controlled attenuation 
parameter (CAP) and secondary objectives were to assess 
the diagnostic accuracy of liver stiffness measurement 
(LSM) by vibration-controlled transient elastography 
(VCTE), comparing CAP and LSM by VCTE with other 
non-invasive tests and also to develop a score combining 
LSM by VCTE, CAP, and biological markers to diagnose 
NASH. Results for the identification of steatosis and 
fibrosis were reported by Eddowes and colleagues,11 
whereas we report the prespecified secondary objective of 
the development of a score to identify patients with NASH 
and significant liver cell injury and fibrosis.
Participants
Eligible patients were aged 18 years or older, able to give 
written informed consent, and scheduled (indep endently 
from this study) to have a liver biopsy for investigation of 
suspected NAFLD (usually as a result of abnormal liver 
enzymes and an ultrasound scan showing an echobright 
liver) within 2 weeks before or after LSM by VCTE and 
CAP measurements. All patients gave written informed 
Research in context
Evidence before this study
Existing diagnostic scores focus only on fibrosis and have not 
been successful in enhancing screen failure rates in clinical trials. 
The concept of identifying patients with non-alcoholic 
steatohepatitis, an elevated non-alcoholic fatty liver disease 
activity score, and F2 fibrosis for the purpose of inclusion in 
clinical trials had not been previously considered. PubMed 
searches for those terms up to September, 2019, with no 
language restrictions, did not reveal any publications in this 
area. Previous studies had only focused on identifying patients 
with fibrosis but not concomitant evaluation of inflammation.
Added value of this study
This study provides a solution to better identify patients who 
might be candidates for clinical trials or treatments as they 
become available. There is a high screen failure rate at liver 
biopsy because of the absence of such tools. This score will 
reduce the number of patients having unnecessary liver 
biopsy.
Implications of all the available evidence
The results of this study have the potential to help clinicians 
and investigators in their decision making, to better select 
patients for clinical trials or access to emerging therapies, and 
streamline the need for liver biopsies among patients with 
non-alcoholic steatohepatitis in clinical care, probably 
resulting in a reduction in the number of biopsies required. 
Future research should focus on studying the performance of 
the FAST (FibroScan-AST) score in primary care.
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consent to participate in the study. Eligible patients were 
negative for hepatitis B surface antigen, anti-hepatitis C 
virus antibody, hepatitis C virus RNA, and hepatitis B 
virus DNA. Patients were excluded in case of ascites, 
pregnancy, active implantable medical device (such as 
pacemaker or defibrillator), liver trans plantation, cardiac 
failure or clinically significant valvular disease, haemo-
chromatosis, refusal to have liver biopsy or blood tests, 
alcohol consumption above recom mended limits 
(>14 units per week for women and >21 units per week 
for men), diagnosis of active malignancy or other 
terminal disease, or participation in another clinical trial 
within the previous 30 days. Age, sex, body-mass index 
(BMI), and presence of diabetes, hypertension, and 
hyper cholesterolaemia were recorded for each patient. A 
12 h fasting blood sample was obtained locally and then 
shipped to a central laboratory for assessment.
Procedures
Percutaneous liver biopsy was done in all patients and 
used as the reference. Specimens were fixed in formalin, 
embedded in paraffin, and stained with haematoxylin and 
eosin and Picrosirius red. Slides were analysed 
independently by two experienced pathologists (PB, VP) 
masked to each other’s reading, and to the patient’s 
clinical and FibroScan data. In case of disagreement, they 
reviewed the slides together to reach consensus. Steatosis, 
ballooning, lobular inflammation grades, fibrosis stage, 
and NAS were assessed using the NASH Clinical Research 
Network (CRN) scoring system.10 NASH was diagnosed 
using the fatty liver: inhibition of progression (FLIP) 
definition (at least grade one for steatosis, ballooning, and 
lobular inflammation).15
LSM by VCTE and CAP were both measured using 
FibroScan 502 Touch devices equipped with both M and 
XL probes (Echosens, Paris, France) by nurses or 
physicians trained and certified by the manufacturer and 
masked to the patient’s histological evaluation.16,17 Patients 
were asked to fast for at least 3 h before the examination. 
Probe selection was done using the automatic probe 
selection tool embedded in the device software. Patients 
were placed in the supine position with their right arm 
fully abducted, and measurements were done by scanning 
the right liver lobe through an intercostal space. CAP is 
an average estimate of ultrasound attenuation at 3·5 MHz 
and is expressed in dB/m. LSM by VCTE is an average 
estimate of stiffness (Young’s modulus) at a shear wave 
frequency of 50 Hz and is expressed as kPa. Only 
examinations with at least ten valid individual 
measurements were deemed valid.
Outcomes and predictor variables
The main outcome was the diagnosis of NASH (using 
FLIP definition) with NAS 4 or higher, and fibrosis 
stage 2 or higher (NAS and fibrosis stage scored using 
CRN scoring system; combination of criteria hereafter 
referred to as NASH + NAS ≥ 4 + F ≥ 2). The models 
considered five predictor variables: LSM by VCTE, CAP, 
aspartate aminotransferase (AST), alanine amino trans-
ferase (ALT) or AST:ALT ratio (AAR). We anticipated that 
only one of AST, ALT, and AAR would be included in the 
final model.
External validation cohorts
Data from seven clinical studies were gathered to perform 
the external validation of the score. Data came from North 
America, Europe, and Asia. Five cohorts came from 
Correspondence to: 
Prof Philip Newsome, 
NIHR Birmingham Biomedical 
Research Centre and Centre for 
Liver and Gastrointestinal 
Research, University of 
Birmingham, Birmingham 
B15 2TT, UK 
p.n.newsome@bham.ac.uk
See Online for appendix
450 participants screened
13 screen failure
 2 liver biopsy not scheduled within 2 weeks of FibroScan
 1 had hepatitis C
 1 had ascites
 1 refused liver biopsy
 1 refused to undergo a blood test
 4 alcohol consumption above limits
 1 confirmed diagnosis of active malignancy
 1 cardiac failure or significant valvular disease
 1 did not consent
 
4 retrospectively excluded because liver biopsy and examination
 with FibroScan were not performed within 2 weeks   
433 eligible
2 no examination with FibroScan because did not attend
 appointment
16 no examination with FibroScan and no liver biopsy
 6 withdrew consent
 2 appointments could not be scheduled within 2 weeks
 5 patients did not attend appointment
 1 investigator decision, no longer eligible for the study
 2 serious adverse events not related to the study device
11 invalid examination with FibroScan
4 no liver biopsy because investigator cancelled biopsy
3 no liver biopsy results because slides were lost
14 biopsy not interpretable
383 with FibroScan examination and biopsy results
33 not biopsy proven non-alcoholic fatty liver disease or normal liver 
350 for score construction
Figure 1: Derivation cohort trial profile
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Derivation 
cohort
French bariatric 
surgery cohort
USA screening 
cohort
China Hong-
Kong NAFLD 
cohort
China 
Wenzhou 
NAFLD cohort
French NAFLD 
cohort
Malaysian 
NAFLD cohort
Turkish NAFLD 
cohort
Pooled external 
patients cohort
Demographics
n 350 110 242 83 104 182 176 129 1026
Age (years) 54 (45–63) 41 (33–50) 55 (50–60) 55 (46–63) 41 (30–50) 58 (49–66) 52 (46–60) 49 (38–57) 52 (44–60)
Female 149 (43%) 88 (80%) 97 (40%) 42 (51%) 28 (27%) 65 (36%) 84 (48%) 59 (46%) 463 (45%)
Male 201 (57%) 22 (20%) 145 (60%) 41 (49%) 76 (73%) 117 (64%) 92 (52%) 70 (54%) 563 (55%)
BMI (kg/m²) 34·2 
(29·6–38·6)
43·0  
(38·8–47·2)
32·6 
(30·0–36·1)
28·9  
(26·0–31·9)
25·5 
(23·4–27·6)
31·6  
(28·6–37·2)
28·1 
(25·9–30·0)
33·0  
(30·0–36·0)
31·0  
(27·7–36·1)
Metabolic
Diabetes (type 1 and 2) 176 (50%) 25 (23%) 55 (23%) 54 (65%) 26 (25%) 86 (47%) 90 (51%) 79 (61%) 415 (40%)
Hypertension 189 (54%) 29 (26%) 113 (47%) 57 (69%) 17 (16%) ·· 104 (59%) 69 (53%) 389 (46%)
Blood
AST (IU/L) 36 (27–52) 26 (21–39) 22 (18–27) 41 (28–59) 34 (27–52) 36 (28–50) 38 (29–62) 37 (28–59) 32 (23–48)
ALT (IU/L) 50 (34–72) 37 (31–54) 25 (19–38) 65 (32–97) 48 (32–88) 48 (32–77) 63 (43–104) 54 (34–106) 44 (28–74)
GGT (IU/L) 57 (34–113) 36 (23–52) 27 (20–40) 56 (37–90) 50 (28–77) 68 (37–131) 74 (41–122) 54 (34–86) 46 (28–85)
Albumin (g/L) 4·5 (4·3–4·7) 3·9 (3·7–4·1) 4·3 (4·1–4·5) 4·3 (3·9–4·6) 4·8 (4·5–5·0) 4·3 (4·0–4·5) 4·3 (4·1–4·6) 4·6 (4·3–4·8) 4·4 (4·1–4·6)
Platelets count (x 10⁹/L) 239 (199–281) 247 (216–283) 236 (201–285) 225 (178–263) 237 (206–266) 223 (170–269) 272 (228–316) 222 (190–267) 238 (199–284)
Fasting glucose (mg/dL) 108 (91–142) 88 (79–103) 103 (93–120) 117 (99–141) 92 (86–108) 111 (99–141) 105 (94–128) 109 (96–126) 104 (92–125)
Triglyceride (mg/dL) 163 (119–213) 130 (100–170) 135 (94–190) 150 (115–221) 178 (116–272) ·· 133 (106–168) 169 (116–227) 146 (106–197)
Total cholesterol 
(mg/dL)
181 (147–212) 192 (167–221) 190 (158–217) 181 (154–207) 184 (150–217) ·· 181 (162–216) 214 (182–242) 190 (161–220)
HDL cholesterol 
(mg/dL)
42 (34–50) 50 (40–60) 48 (39–58) 46 (39–50) 36 (33–42) ·· 45 (39–52) 44 (39–53) 45 (38–54)
Fibrosis scores
FIB-4 1·13  
(0·78–1·68)
0·69  
(0·48–1·11)
0·99  
(0·81–1·31)
1·27  
(0·96–1·72)
0·91  
(0·62–1·20)
1·38  
(0·90–1·96)
0·96  
(0·65–1·40)
1·17  
(0·79–1·59)
1·04  
(0·72–1·46)
NFS –1·00 
(–2·12 to 0·08)
–0·80 
(–2·17 to 0·08)
–0·97 
(–1·90 to 0·04)
–0·95 
(–2·04 to 0·16)
–2·77 
(–3·61 to 1·87)
–0·60 
(–1·38 to 0·57)
–2·16 
(–3·04 to 1·17)
–1·12 
(–1·80 to 0·22)
–1·28 
(–2·32 to 0·24)
FibroScan
Probe size
M 111 (32%) 10 (9%) 141 (58%) 63 (76%) 104 (100%) 99 (54%) 176 (100%) 68 (53%) 661 (64%)
XL 239 (68%) 100 (91%) 101 (42%) 20 (24%) 0 83 (46%) 0 61 (47%) 365 (36%)
LSM by VCTE (kPa) 8·9  
(6·2–13·9)
5·9  
(4·7–8·8)
6·0  
(4·7–8·2)
8·8  
(6·6–12·2)
5·8  
(5·1–6·7)
7·9  
(5·9–11·5)
7  
(6–10)
11·1  
(8·6–14·6)
7·2  
(5·3–10·3)
CAP (dB/m) 342  
(307–373)
310  
(275–374)
317  
(276–360)
319  
(290–354)
316  
(284–332)
326  
(297–369)
323  
(289–343)
329  
(304–356)
321  
(288–355)
Histology
Length of liver biopsy
specimen (mm)
23 (10) 12 (5) 14 (5) 23 (8) ·· 29 (11) 15 (4) 30 (14) 17 (12)
Length of liver biopsy 
specimen ≥15 mm
315 (90%) 50 (45%) 109 (45%) 74 (89%) ·· 169 (93%) 102 (58%) 125 (98%) 629 (68%)
Fibrosis stage
0 60 (17%) 65 (59%) 131 (54%) 9 (11%) 45 (43%) 28 (15%) 62 (35%) 16 (12%) 356 (35%)
1 80 (23%) 26 (24%) 74 (31%) 23 (28%) 46 (44%) 46 (25%) 73 (41%) 37 (29%) 325 (32%)
2 81 (23%) 9 (8%) 26 (11%) 15 (18%) 8 (8%) 46 (25%) 12 (7%) 30 (23%) 146 (14%)
3 101 (29%) 9 (8%) 11 (5%) 17 (20%) 5 (5%) 53 (29%) 24 (14%) 33 (26%) 152 (15%)
4 28 (8%) 1 (1%) 0 19 (23%) 0 9 (5%) 5 (3%) 13 (10%) 47 (5%)
Ballooning grade
0 78 (22%) 64 (58%) 127 (52%) 35 (42%) 28 (27%) 44 (24%) 58 (33%) 5 (4%) 361 (35%)
1 142 (41%) 35 (32%) 92 (38%) 39 (47%) 63 (61%) 73 (40%) 78 (44%) 64 (50%) 444 (43%)
2 130 (37%) 11 (10%) 23 (10%) 9 (11%) 13 (12%) 65 (36%) 40 (23%) 60 (47%) 221 (22%)
(Table 1 continues on next page)
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tertiary care liver centres, one cohort came from a bariatric 
surgery centre, and one cohort came from a study of 
screening for NAFLD in patients having a routine 
colonoscopy. All external validation cohort data were 
collected in the framework of a clinical study for which the 
local ethical committee granted approval. All patients 
from each study gave written informed consent to 
participate in the study. Each study was done in accordance 
with the Declaration of Helsinki and in agreement with 
the International Conference on Harmonisation 
guidelines on Good Clinical Practice. Enrolment dates of 
each study are shown in the appendix (p 5) together with 
descriptions of external validation cohorts. Datasets were 
locked at the date of the last inclusion (appendix p 5). 
However, the Chinese Wenzhou, French, and Turkish 
NAFLD studies were ongoing at database lock (Wenzhou 
was expected to end in December, 2022, the French open 
registry had no planned termination date, and the Turkish 
study terminated in May, 2019). In each external validation 
study, patients were recruited consecutively, FibroScan 
operators were masked to patients’ clinical data, and all 
liver biopsy results were read by expert pathologists who 
were masked to patient clinical data and FibroScan device 
results. For the two studies that had all patients measured 
with both M and XL probes (Chinese Hong-Kong and 
French NAFLD cohorts), the FibroScan examination 
corresponding to the XL probe was considered if the 
patient’s BMI was greater or equal to 32 kg/m²; otherwise 
the M probe was considered.
All external validation cohorts excluded patients who 
met the following criteria: non-metabolic comorbidities 
that could have induced liver lesions such as viral 
hepatitis, drug-induced liver injury, excessive alcohol 
consumption, or HIV; BMI higher than 32 kg/m² if only 
the M probe was available for the study; less than ten 
valid measurements for FibroScan; missing data for the 
developed score; liver biopsy results that were non-
interpretable or with missing data for the target of 
NASH + NAS ≥ 4 + F ≥ 2; or a time interval greater than 
1 year between FibroScan and liver biopsy. In each 
external validation cohort, patients had their individual 
lesions of steatosis, lobular inflam mation, ballooning 
Derivation 
cohort
French bariatric 
surgery cohort
USA screening 
cohort
China Hong-
Kong NAFLD 
cohort
China 
Wenzhou 
NAFLD cohort
French NAFLD 
cohort
Malaysian 
NAFLD cohort
Turkish NAFLD 
cohort
Pooled external 
patients cohort
(Continued from previous page)
Lobular inflammation grade
0 72 (21%) 71 (65%) 110 (45%) 0 18 (17%) 38 (21%) 3 (2%) 2 (2%) 242 (24%)
1 224 (64%) 33 (30%) 111 (46%) 35 (42%) 66 (63%) 123 (68%) 100 (57%) 51 (40%) 519 (51%)
2 50 (14%) 5 (5%) 20 (8%) 45 (54%) 17 (16%) 21 (12%) 67 (38%) 49 (38%) 224 (22%)
3 4 (1%) 1 (1%) 1 (<1%) 3 (4%) 3 (3%) 0 6 (3%) 27 (21%) 41 (4%)
Steatosis grade
0 17 (5%) 37 (34%) 56 (23%) 0 0 12 (7%) 4 (2%) 0 109 (11%)
1 87 (25%) 27 (25%) 90 (37%) 34 (41%) 44 (42%) 81 (45%) 48 (27%) 18 (14%) 342 (33%)
2 108 (31%) 21 (19%) 56 (23%) 30 (36%) 43 (41%) 48 (26%) 92 (52%) 46 (36%) 336 (33%)
3 138 (39%) 25 (23%) 40 (17%) 19 (23%) 17 (16%) 41 (23%) 32 (18%) 65 (50%) 239 (23%)
NAS score ≥4 239 (68%) 36 (33%) 81 (33%) 50 (60%) 47 (45%) 110 (60%) 115 (65%) 120 (93%) 559 (54%)
NASH 241 (69%) 31 (28%) 92 (38%) 48 (58%) 63 (61%) 122 (67%) 116 (66%) 123 (95%) 595 (58%)
NASH + NAS ≥ 4 + F ≥ 2 174 (50%) 16 (15%) 28 (12%) 36 (43%) 9 (9%) 78 (43%) 36 (20%) 74 (57%) 277 (27%)
Time between procedures (days)
Time between 
FibroScan and liver 
biopsy, median (IQR); 
range
0 (0 to 0);  
–14 to 12
78 (49 to 162); 
–328 to 332
56 (40 to 84); 
–33 to 309
1 (–2 to 1); 
–95 to 161
0 (0 to 0); 
–84 to 9
0 (0 to 0);  
0 to 0
0 (0 to 0);  
0 to 0
35 (16 to 113); 
–271 to 360
1 (0 to 55); 
–328 to 360
Time between 
FibroScan and blood 
analyses, median (IQR); 
range
0 (0 to 0);  
–1 to 9
.. 9 (0 to 27); 
–151 to 217
0 (0 to 0);  
0 to 0
0 (0 to 0); 
–84 to 9
0 (0 to 0);  
0 to 0
0 (0 to 0);  
0 to 0
18 (1 to 113); 
–315 to 373
0 (0 to 4); 
–315 to 373
Time between liver 
biopsy and blood 
analyses, median (IQR); 
range
0 (0 to 0);  
–15 to 12
.. –46 (–70 to 22); 
–309 to 93
–1 (–1 to 2); 
–161 to 95
0 (0 to 0); 
0 to 0
0 (0 to 0);  
0 to 0
0 (0 to 0);  
0 to 0
–12 (–31 to 36); 
–435 to 293
0 (–24 to 0); 
–435 to 293
Data are n, median (IQR), n (%), or mean (SD), unless otherwise specified. The NAS and Kleiner scoring system are described in the appendix (p 2). Data are missing from the French cohort because the 
investigator did not agree to share those data. In Malaysia, the BMI criteria for obesity are lower than in Western countries. For the Chinese and Malaysian cohorts the median (IQR), minimum and maximum 
delay were frequently zero because procedures were systematically done on the same day. ALT=alanine aminotransferase. AST=aspartate aminotransferase. BMI=body-mass index. CAP=controlled attenuation 
parameter. FIB-4=fibrosis-4 index. GGT=γ-glutamyl transferase. LSM=liver stiffness measurement. NAFLD=non-alcoholic fatty liver disease. NASH=non-alcoholic steatohepatitis. NAS=NAFLD activity score. 
NFS=NAFLD fibrosis score. VCTE=vibration-controlled transient elastography. 
Table 1: Derivation and external validation cohort patient characteristics
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Figure 2: Diagnostic performance in the derivation cohort of the FAST score for the diagnostic of NASH + NAS ≥ 4 + F ≥ 2
(A) Receiver operating characteristic curve. (B) Calibration plot and calibration intercept and slope. The shaded area indicates 95% CI. The calibration plot characterises 
the agreement between observed proportion and predicted probabilities. The intercept compares the mean of all predicted risks with the mean observed risk and 
indicates the extent that predictions are systematically too low or too high.19 The slope accounts for differences in performance in groups at high or low risk. Calibration 
of the data is estimated using a smoothed regression line (dotted line) using locally estimated scatterplot smoothing (Loess) that allows inspection of the calibration 
across the range of predicted values and determination of whether there are segments of the range in which the model is poorly calibrated.19 Triangles represent deciles 
of participants (n=50) grouped by similar predicted risk. Calibration of the score is satisfactory since the intercept is not significantly different from 0, slope is not 
significantly different from 1, the flexible calibration curve is close to the ideal calibration (solid line), and its CI zone includes the ideal curve. (C) Sensitivity, specificity, 
positive predictive value, and negative predictive value versus all possible FAST score values. (D) Screen failure rate, missed cases rate, and proportion of patients 
identified, versus FAST scores values. Plot of the screen failure rate (equal to 1–positive predictive value) and missed cases rate (equal to 1–sensitivity) versus all possible 
FAST score values. At given FAST score cutoffs, it is possible to graphically assess the screen failure rate and missed cases rate together with the proportion of patients 
above the FAST score who would be given liver biopsy in the context of patients screening in drug trials for NASH. NASH=non-alcoholic steatohepatitis. 
FAST=FibroScan-aspartate aminotransferase. NASH + NAS ≥ 4 + F ≥ 2=NASH, elevated non-alcoholic fatty liver disease activity score (≥4), and advanced fibrosis 
(≥stage 2). AUROC=area under the receiver operating curve.
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grades, and fibrosis stage scored according to the NASH 
CRN scoring system.10 From these individual items, a 
diagnosis of NASH was made according to the FLIP 
definition,15 and the NASH + NAS ≥ 4 + F ≥ 2 outcome 
was computed.
Statistical analysis
Sample size was determined for the primary objective of 
estimating the accuracy of CAP to achieve a 5% standard 
error in the estimates of the area under the receiver 
operating curve (AUROC) parameter in the subgroup 
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using the XL probe. Assuming two-thirds of recruited 
patients would use the XL probe, and allowing for 30% 
dropout, the target sample size was set at 450. This sample 
size was judged adequate to provide robust estimates for 
predictive models based on five covariates, with over 
30 events per variable at an expected prevalence of 50%. 
The score was developed on the 350 patients in the 
derivation cohort. Eight (2%) of 350 patients had missing 
data for CAP, AST, or ALT, and since the proportion of 
observations with missing data was less than 3%, single 
imputation was done using stochastic regression 
imputation.18,19 The selection of parameters was based on 
the combination of LSM by VCTE (related to liver fibrosis), 
and CAP (related to liver steatosis), with factors linked to 
NASH, inflammation, and fibrosis (AST, ALT, AAR). 
Parameters were combined into a multivariable logistic 
regression model. Akaike’s information criterion was 
used to select between AST, ALT, and AAR as the optimal 
parameter to combine to LSM by VCTE and CAP. The 
relative importance of each parameter was appraised 
using the Wald test. Nested models were compared using 
the likelihood ratio test. Optimal exploratory variable 
trans formations were selected using multivariable first-
degree fractional polynomials to optimise the model.20 In 
this method, first order fractional polynomials are 
formulated as a power transformation of the predictors 
taken from the set –2, –1, –0·5, 0, 0·5, 1, 2, 3. Optimal 
power is selected for each predictor (considered in order 
of decreasing statistical significance) using a backward 
stepwise selection procedure.20
The model was internally validated using 2000 bootstrap 
samples.19 Within each bootstrap iteration, we refitted the 
model and evaluated the performance in the bootstrap 
sample (apparent performance) and in the original data 
(test performance). Performance was assessed in terms 
of AUROC. The optimism was quantified as the mean 
differences of the performance estimates, and the 
shrinkage factor computed and applied to each regression 
coefficient in the original model to adjust the model for 
overfitting. Alternative methods such as cross-validation 
could have been used to perform the internal validation 
of the score, but bootstrapping is considered superior to 
cross-validation as it allows quantification of the extent of 
overfitting and optimism.13 Bootstrapping also provides 
an estimate of a correction factor (called shrinkage factor) 
that can be used to adjust the regression coefficients for 
overfitting such that better performance will be obtained 
when applying the score to new patients.
Model performance was assessed by calibration and 
discrimination in both the derivation and validation 
cohorts. Calibration (the agreement between observed 
outcomes and prediction) was assessed using calibration 
plots and a smoothing technique based on locally 
estimated scatterplot smoothing (Loess).19 Discri mination 
was assessed using AUROC (similar to Harrell’s 
C-statistic). Cutoffs for sensitivity (≥0·90) and specificity 
(≥0·90) were derived in the derivation cohort. When 
appraising performance at a given cutoff, sensitivity, 
specificity, positive predictive value (PPV), and negative 
predictive value (NPV) were computed together with 
95% CIs (see appendix p 7 for potential risk of bias in each 
external validation cohort). AUROC comparison was done 
using the Delong test. Statistical analyses were done using 
the software R, version 3.4.1.21 This study is registered with 
ClinicalTrials.gov, NCT01985009.
Role of the funding source
The funder of the study had a role in study design, data 
collection, data analysis, data interpretation and writing 
of the report. The corresponding author and the funder 
had full access to all data in the study and had full 
responsibility for the decision to submit the publication.
Results
Between March 20, 2014, and Jan 17, 2017, we assessed 
450 potentially eligible participants (figure 1), 350 of 
whom were included in the FibroScan-AST (FAST) 
score construction, which was subsequently validated in 
seven cohorts (total of 1026 patients). As reported in 
table 1, the derivation cohort had broadly similar 
demographic, metabolic, serological, and histological 
characteristics to patients in the pooled validation 
cohorts. NASH was reported in 241 (69%) of 350 patients 
in the derivation cohort and 595 (58%) of 1026 patients 
in the pooled validation cohort. NASH + NAS ≥ 4 + F ≥ 2 
Figure 3: Calibration plots in external validation cohorts
(A) French bariatric cohort (n=110). Prevalence of NASH + NAS ≥ 4 + F ≥ 2=15%. 
(B) USA screening cohort (n=242). Prevalence of NASH + NAS ≥ 4 + F ≥ 2=12%. 
(C) China Hong-Kong NAFLD cohort (n=83). Prevalence of 
NASH+NAS≥4+F≥2=43%. (D) China Wenzhou NAFLD cohort (n=104). 
Prevalence of NASH + NAS ≥ 4 + F ≥ 2=9%. (E) French NAFLD cohort (n=182). 
Prevalence of NASH + NAS ≥ 4 + F ≥ 2=43%. (F) Malaysian NAFLD cohort 
(n=176). Prevalence of NASH + NAS ≥ 4 + F ≥ 2=20%. (G) Turkish NAFLD cohort 
(n=129). Prevalence of NASH + NAS ≥ 4 + F ≥ 2=57%. The solid line in each image 
represents the ideal calibration. The dotted line represents the calibrations 
estimated on the data using locally estimated scatterplot smoothing (Loess). 
The shaded area indicates 95% CI. Triangles represent deciles of participants 
grouped by similar predicted risk. The distribution of participants is indicated 
with spikes at the bottom of the graph (patients with NASH + NAS ≥ 4 + F ≥ 2 
above the x-axis, patients without NASH + NAS ≥ 4 + F ≥ 2 below the x-axis). 
The French (E) and Turkish (G) NAFLD external validation cohorts are well 
calibrated; their calibration curve is nearly linear, their intercept is close to zero 
(CIs include zero), and their slope is close to one (CIs include one). The Chinese 
Hong-Kong NAFLD cohort (C) has a zone in which the risk of being 
NASH + NAS ≥ 4 + F ≥ 2 is overestimated using the FAST score (grey ribbon 
below the ideal calibration curve) and a zone in which the calibration seem 
adequate (grey ribbon zone includes the ideal calibration curve). However, this 
cohort size is quite small (n=83). The French bariatric surgery (A), USA 
screening (B), Chinese Wenzhou NALFD (D), and the Malaysian NAFLD (F) 
cohort have a range of prevalence of NASH + NAS ≥ 4 + F ≥ 2 (9% to 20%), which 
is lower than the derivation cohort. In those four cohorts, the FAST score 
overestimates the probability of being NASH + NAS ≥ 4 + F ≥ 2. The discrepancy 
is mainly driven by the intercept (CIs do not include zero). All slopes are within 
an acceptable range (the CI includes one), except for the French bariatric cohort, 
which seems to be at the limit. NAFLD=non-alcoholic fatty liver disease. 
FAST=FibroScan-aspartate aminotransferase. NASH + NAS ≥ 4 + F ≥ 2=non-
alcoholic steatohepatitis, elevated non-alcoholic fatty liver disease activity 
score (≥4) and advanced fibrosis (≥stage 2). 
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was reported in 174 (50%) of 350 patients in the 
derivation cohort and 277 (27%) of 1026 patients in the 
pooled validation cohort.
Models combining LSM by VCTE; CAP; and AST, ALT, 
or AAR were compared (appendix p 9). AST was 
determined to be the best parameter to combine with 
LSM and CAP. Further nested model comparison was 
done (appendix p 10), which showed that a model 
combining LSM, CAP, and AST had significantly better 
predictive properties than models with only one or two of 
these predictors. This resulted in the following equation 
for the FAST score:
The FAST score was sensitive to each individual 
histological component (appendix p 20). As the derived 
FAST score is the predicted probability from the logistic 
regression model it is bounded between 0 and 1, and 
can be interpreted in a probabilistic manner. AUROC 
in the bootstrap sample (apparent performance) was 
0·803 (95% CI 0·758–0·849) and in the original data 
(test performance) 0·804 (0·790–0·806), showing little 
over-optimism (–6·0 × 10–⁴, –4·3 × 10–² to 4·7 × 10–²). 
Predictive performance of FAST score in terms of 
discrimination, calibration, and diagnostic accuracy 
(figure 2) indicated an AUROC of 0·80 (95% CI 
0·76–0·85) with satisfactory calibration of predicted 
probabilities.
Diagnostic performance of FAST score in terms of 
sensitivity, specificity, and positive and negative 
predictive values is represented in figure 2C by cutoff 
value. Figure 2D illustrates the performance of FAST 
score as it might be used in the context of identifying 
patients for therapies or drug trials for NASH. The 
screen failure rate represents the proportion of screened 
participants having liver biopsy that would not meet the 
histological target (NASH + NAS ≥ 4 + F ≥ 2) and would 
therefore not be randomised in trials or considered for 
treatment. If FAST score was used to identify such 
patients, the screen failure rate would decrease from 
174 (50%) of 350 patients  with increasing FAST cutoffs 
as illustrated in figure 2D, although more patients would 
be identified as false negatives for NASH + NAS ≥ 4 + F ≥ 2 
(missed case rate). The histological characteristics of 
misclassified patients are detailed in the appendix (p 19).
External validation of the score was evaluated alongside 
calibration plots for each external validation cohort 
(figure 3). Calibration was satisfactory for the Chinese 
Hong-Kong, French, and Turkish NAFLD cohorts, which 
have a prevalence of NASH + NAS ≥ 4 + F ≥ 2 similar to the 
AUROC 
(95% CI)
n Prevalence of 
NASH + NAS ≥ 4 + F ≥ 2
Rule-out zone (FAST ≤0·35) Grey zone 
(FAST 
0·35–0·67), 
n (%)
Rule-in zone (FAST ≥0·67)
n (%) Sensitivity Specificity NPV n (%) Specificity Sensitivity PPV
Derivation cohort 0·80 
(0·76–0·85)
350 174 (50%) 113 (32%) 0·90 
(157/174)
0·53 
(93/176)
0·85 
(93/110)
136 (39%) 101 (29%) 0·90 
(159/176)
0·48 
(84/174)
0·83 
(84/101)
French bariatric 
surgery cohort
0·95 
(0·91–0·99)
110 16 (15%) 69 (63%) 1·00 
(16/16)
0·73 
(69/94)
1·00 
(69/69)
22 (20%) 19 (17%) 0·93 
(87/94)
0·75 
(12/16)
0·63 
(12/19)
USA screening 
cohort
0·86 
(0·80–0·93)
242 28 (12%) 194 (80%) 0·64 
(18/28)
0·86 
(183/214)
0·95 
(183/193)
39 (16%) 9 (4%) 0·99 
(212/214)
0·25  
(7/28)
0·78 (7/9)
China Hong-Kong 
NAFLD cohort
0·85 
(0·76–0·93)
83 36 (43%) 28 (34%) 0·94
(34/36)
0·55
(26/47)
0·93
(26/28)
29 (35%) 26 (31%) 0·89 
(42/47)
0·58 
(21/36)
0·81 
(21/26)
China Wenzhou 
NAFLD cohort
0·84 
(0·73–0·95)
104 9 (9%) 55 (53%) 0·89  
(8/9)
0·56 
(53/95)
0·98 
(58/67)
37 (36%) 12 (11%) 0·92 
(87/95)
0·44  
(4/9)
0·33 
(4/12)
French NAFLD 
cohort
0·80 
(0·73–0·86)
182 78 (43%) 67 (37%) 0·88 
(69/78)
0·56 
(58/104)
0·87 
(58/67)
69 (38%) 46 (24%) 0·89 
(93/104)
0·45 
(35/78)
0·76 
(35/46)
Malaysian NAFLD 
cohort
0·85 
(0·78–0·91)
176 36 (20%) 78 (44%) 0·94 
(34/36)
0·54 
(75/140)
0·97 
(75/77)
59 (34%) 39 (22%) 0·87 
(122/140)
0·58 
(21/36)
0·54 
(21/39)
Turkish NAFLD 
cohort
0·74 
(0·65–0·82)
129 74 (57%) 26 (20%) 0·91 
(67/74)
0·35 
(19/55)
0·73 
(19/26)
57 (44%) 46 (36%) 0·82 
(45/55)
0·49 
(36/74)
0·78 
(36/46)
Pooled external 
patients cohort
0·85 
(0·83–0·87)
1026 277 (27%) 517 (51%) 0·89 
(246/277)
0·64 
(483/749)
0·94 
(483/514)
312 (30%) 197 (19%) 0·92 
(688/749)
0·49 
(136/277)
0·69 
(136/197)
Performance associated with dual cutoff approach is evaluated using the FAST score when the cutoffs are calculated in the derivation cohort and applied in all external validation cohorts. The lower cutoff 
constitutes a rule-out cutoff and is based on a sensitivity ≥0·90 in the derivation cohort. The higher cutoff constitutes a rule-in cutoff and is based on a specificity ≥0·90 in the derivation cohort. Individuals with a 
FAST score in between the rule-out and rule-in cutoffs are in the grey zone. In the rule-out group, the sensitivity is provided together with the specificity and NPV to appraise the rule-out performance of the 
score. In the rule-in group, the specificity is provided together with the sensitivity and PPV to appraise the rule-in performance of the score. AUROC=area under the receiver operating curve. FAST=FibroScan-
aspartate aminotransferase. NAFLD=non-alcoholic fatty liver disease. NASH=non-alcoholic steatohepatitis. NAS=NAFLD activity score. NASH + NAS ≥ 4 + F ≥ 2=NASH and NAS≥4 and advanced fibrosis 
(≥stage 2). NPV=negative predictive value. PPV=positive predictive value. 
Table 2: Diagnostic performance of the FAST score for the diagnosis of NASH + NAS ≥ 4 + F ≥ 2 in the derivation and external validation cohorts
FAST =
1 + e – 1·65 + 1·07 × In(LSM) + 2·66*10–⁸ × CAP³ – 63∤3 × AST–¹
e – 1·65 + 1·07 × In(LSM) + 2·66*10–⁸ × CAP³ – 63∤3 × AST–¹
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derivation cohort. However, for cohorts with a lower 
prevalence of the outcome, FAST score overestimates 
the probability of having NASH + NAS ≥ 4 + F ≥ 2. Corres-
ponding AUROCs are provided (table 2), with good to 
excellent discrimination in all external validation cohorts 
except for the Turkish NAFLD cohort, which had modest 
performance. Best discrimination was observed in the 
French bariatric surgery cohort, with an AUROC of 0·95 
(95% CI 0·91–0·99).
Cutoff for sensitivity (≥0·90) was 0·35 and for specificity 
(≥0·90) was 0·67 in the derivation cohort (full diagnostic 
performance in the appendix, p 11), with characteristics 
for validation cohorts detailed in table 2. Using the dual 
cutoff approach, PPV in the derivation cohort was 0·83 
(84/[84+17], 95% CI 0·75–0·87), NPV was 0·85 (93/[93+17], 
0·77–0·88), and 136 (39%) of 350 patients were in the grey 
zone between the two cutoffs. When applying these 
cutoffs to the external validation cohorts, PPV was in the 
same order of magnitude with a similar sensitivity in the 
Chinese Hong-Kong, French, and Turkish NAFLD 
cohorts. The USA screening cohort had a PPV in the same 
order of magnitude but a lower sensitivity. The Chinese 
Wenzhou NAFLD with the lowest prevalence of 
NASH + NAS ≥ 4 + F ≥ 2, had a lower PPV but similar 
sensitivity. NPV was high in all external validation cohorts.
FAST was compared with FIB-4 and the NAFLD fibrosis 
score (NFS) for the identification of patients with 
NASH + NAS ≥ 4 + F ≥ 2 in the subgroup of patients from 
the derivation and external validation cohorts that had all 
parameters needed to compute those three scores 
(derivation cohort n=339, pooled external validation cohort 
n=981). Corresponding AUROCs and diagnostic perfor-
mance using the dual cutoff approach (appendix p 12) were 
inferior to the FAST score. Indeed, discrimination was 
significantly higher for the FAST score in the derivation 
and in the pooled external validation cohort. Using the 
dual cutoff approach in the pooled validation cohort, 
NASH + NAS ≥ 4 + F ≥ 2 yielded a similar number of 
patients in the grey zone (311 [32%] of 981 patients) as did 
FAST (304 [31%]), NASH + NAS ≥ 4 + F ≥ 2 yielded a slightly 
higher PPV (0·72 [18/25] with NASH + NAS ≥ 4 + F ≥ 2 vs 
0·69 [132/190] with FAST), but lower NPV (0·83 [536/645] 
with NASH + NAS ≥ 4 + F ≥ 2 vs 0·94 [453/484] with FAST), 
and failed to identify most of the patients with 
NASH+NAS≥4+F≥2 (sensitivity 0·07 [18/272] with 
NASH + NAS ≥ 4 + F ≥ 2 vs 0·49 [132/272] with FAST). NFS 
had a larger grey zone than FAST (444 [45%] of 981 patients 
with NFS vs 304 [31%] of 981 patients with FAST) with 
lower PPV (NFS 0·50 [51/101] vs FAST 0·69 [132/190]) and 
NPV (NFS 0·85 [370/436] vs FAST 0·94 [453/484]). 
Moreover, the addition of metabolic para meters to the 
score were appraised and did not provide significant 
improvement in terms of discrimination (appendix p 15).
Discussion
In this prospective cohort study, we present a new, 
simple, non-proprietary score that identifies patients 
with progressive NASH and has been validated in 
multiple large global cohorts.
There has been considerable debate as to which 
patients with NASH should be the focus of monitoring 
and treatment, although data have suggested that the 
degree of fibrosis is a major driver of clinical 
outcomes.22–24 Our choice of NASH with NAS ≥ 4 and 
F ≥ 2 is based on this literature and also many therapeutic 
studies that show the presence of elevated necro-
inflammatory activity is linked to progressive injury and 
pharma cological response.12,25
The FAST score, in keeping with recommended 
practice, was configured to have two thresholds, a rule-
out and a rule-in cutoff. This allowed for classification 
of more than 70% of patients in the validation cohorts. 
Moreover, FAST score has good performance chara-
cteristics with a negative likelihood ratio of 0·2 (rule-
out, cutoff) and a positive likelihood ratio of 5 (rule-in, 
cutoff), ratios that are maintained in the validation 
groups. Thus, this test could have a substantial influence 
on clinical decision making and be an important adjunct 
in identifying patients for clinical trials or com-
mencement of pharmacotherapies. 33 patients had 
types of lesion on their biopsy samples that were neither 
in-keeping with NAFLD nor were normal. Although 
some of these patients had some fibrosis or steatosis, 
the pathologist did not feel it was appropriate to grade 
them for items of the NAS or fibrosis according to the 
NASH CRN scoring system, which would have biased 
the construction of the score. We therefore decided to 
build the score using a completely NAFLD cohort. 
Although this might affect the performance of the score 
in the derivation cohort, it would have no effect on 
performance in the multiple validation cohorts.
As with any other predictive models, the performance 
of the FAST score will be determined by the population 
to which it is applied: the spectrum bias will affect the 
sensitivity and specificity of the score, and the prevalence 
of the target patients will affect predictive values.26 For 
example, the PPV of any test will be different in primary 
versus secondary care, although the NPV will remain 
robust. This test will be of greatest value in secondary 
care, in which consideration for biopsy and eligibility for 
trials or treatment will be evaluated. These patients will 
inevitably have received some form of vetting, but we 
know from screening data for clinical trials that there 
is a high rate of screen failure for trials. We believe the 
FAST score will help to identify the patients suitable for 
clinical trials and emerging therapies more efficiently 
and reduce unnecessary liver biopsies.
Using such tools is inevitably a trade-off between 
reducing false positives and avoiding too many false 
negatives. This requires an understanding of the relative 
impact of these effects (ie, fewer biopsies and the 
potential problems that result from patients not being 
considered for treatment), which is limited, and the 
efficacy of new treatments is unknown.
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In generating this score, we sought to determine the 
performance of standard liver blood tests or other widely 
used algorithms in identifying patients with progressive 
NASH. The performance of these parameters in isolation 
was inferior to the FAST score (appendix p 9), and indeed 
other than the addition of AST values, there was no 
evidence that addition of other elements (eg, metabolic 
syndrome parameters) improved the perfor mance of the 
FAST score (appendix p 15).
One of the challenges with such tests is dealing with 
patients in the grey zone. Decision making for such 
patients will be influenced by individual characteristics, 
proximity to thresholds (low or high), and operator 
confidence. In many cases, it might be appropriate to 
repeat the test at a suitable interval (eg, 2–3 months), 
whereas in others it might be useful to consider an 
alternative modality or proceed with liver biopsy. Patient 
choice will be a key determinant of this decision making.
We, and others, have shown that CAP and LSM by VCTE 
measurements are widely applicable in patients with 
NASH, with a low failure rate (3%) and good performance 
in determining the degree of liver steatosis and fibrosis.11,27 
Importantly, we also showed that LSM values only 
correlated with fibrosis, and were not influenced by other 
histological parameters or type of probe used.
Our study has several strengths. Firstly, it is prospective 
in nature and has undergone extensive validation across 
multiple large global cohorts. Secondly, FAST score 
performance is good across the full range of validation 
cohorts. AUROC ranged from 0·74 to 0·95, with PPV up 
to 0·85 and NPV ranging from 0·73 to 1 using the dual 
cutoffs approach, with cutoffs derived in the derivation 
cohort. Thirdly, the wide availability of FibroScan devices 
based on VCTE technology, the need for just a serum 
AST value, its non-invasive nature, its low cost per scan, 
and its modest requirement to attain technical 
proficiency required to do the scans, mean the method 
can be rolled out easily across most clinical practices. 
Roll-out is further aided by the free availability of the 
equation, which is also accessible through an app.
There are several weaknesses to this study, including 
the requirement for a FibroScan device, which could 
affect uptake. Use of FAST in primary care will require 
investment in devices and personnel, although there are 
many examples of such models being introduced 
successfully.6 Another potential criticism is that our 
score focuses on patients with fibrosis stage 2 or higher, 
with some contending that identifying patients with 
more advanced fibrosis (≥stage 3) should be the priority. 
At this stage, clinical trials are aiming to recruit patients 
with stage 2 and 3 fibrosis, and we therefore believe that 
stage 2 fibrosis and above constitutes a reasonable target 
group. We derived cutoffs for the identification of 
patients with advanced fibrosis (F≥3) in our cohort 
(appendix p 16,17). The performance characteristics 
were good, with moderate likelihood ratios to rule-out 
and rule-in such patients.
In two validation cohorts there was only access to the 
M probe, so patients with a BMI greater than 32 kg/m² were 
excluded, which could bias the performance of the score in 
those cohorts.
Finally, FAST score performed least well in terms of 
calibration in low prevalence populations, and caution 
should be exercised when interpreting the score in these 
settings, although discrimination performance of the 
score was good. In a future study, recalibration of scores 
could be considered to correct miscalibration while 
keeping the same level of discrimination. However, to 
do so we need to know which prevalence would be 
representative of the population, in whom the score 
would be used, and a robust reference cohort with that 
low prevalence.
In summary, we believe the FAST score will allow for 
the more efficient identification of an at-risk group of 
patients with progressive NASH that merit consideration 
for further treatment.
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